论文标题
PET患者内部剂量法的定量II:基于蒙特卡洛的个性化剂量法
Quantification of internal dosimetry in PET patients II: Individualized Monte Carlo-based dosimetry for [18F]Fluorocholine PET
论文作者
论文摘要
目的:在接受诊断性FCH-PET研究的患者中,用蒙特卡洛法获得个性化的内剂量,并将这种剂量与MIRD方法计算进行比较。方法:静脉内施用平均FCH活性为244.3 MBQ后,成像了17名男性的患者队列。处理所得的PET/CT图像是为了生成个性化输入源和几何文件,以使用MC工具门计算剂量。研究了所得剂量估计值并将其与具有两个不同计算幻象的Mird方法进行了比较。尽可能对S因子进行质量校正。仔细检查了潜在的不确定性来源:部分身体图像,膀胱排空和生物动力学建模的影响。 结果:发现我们的方法论和MIRD方法之间的剂量差异很大,通常在$ \ pm $ 25%的范围内,在某些情况下最高$ \ pm $ 120%。质量缩放表现出改善,尤其是对于非壁和高摄取组织。除前列腺外,对膀胱排空的模拟对其他器官的剂量显示出可忽略不计的作用。基于部分PET/CT图像(不包括腿)的剂量测定导致对骨,皮肤和剩余组织的平均剂量过高估计,以及其他器官/组织中的较小差异。与FCH的生物动力学相关的估计不确定性引入了累积活动的变化范围在$ \ pm $ \ pm $ 10%的高摄取器官中。 结论:MC方法比MIRD方法学允许更高程度的剂量学个性化,这在某些情况下会导致剂量值的重要差异。基于单个部分宠物研究的FCH-PET的剂量法似乎是由于FCH的特殊生物动力学,即使某些校正因子可能需要用于估计平均皮肤/骨剂量。
Purpose: To obtain individualized internal doses with a Monte Carlo method in patients undergoing diagnostic FCH-PET studies and to compare such doses with the MIRD method calculations. Methods: A patient cohort of 17 males were imaged after intravenous administration of a mean FCH activity of 244.3 MBq. The resulting PET/CT images were processed in order to generate individualized input source and geometry files for dose computation with the MC tool GATE. The resulting dose estimates were studied and compared to the MIRD method with two different computational phantoms. Mass correction of the S-factors was applied when possible. Potential sources of uncertainty were closely examined: the effect of partial body images, urinary bladder emptying, and biokinetic modeling. Results: Large differences in doses between our methodology and the MIRD method were found, generally in the range of $\pm$25%, and up to $\pm$120% for some cases. The mass scaling showed improvements, especially for non-walled and high-uptake tissues. Simulations of the urinary bladder emptying showed negligible effects on doses to other organs, with the exception of the prostate. Dosimetry based on partial PET/CT images (excluding the legs) resulted in an over-estimation of mean doses to bone, skin, and remaining tissues, and minor differences in other organs/tissues. Estimated uncertainties associated with the biokinetics of FCH introduce variations of cumulated activities in the range of $\pm$10% in the high-uptake organs. Conclusions: The MC methodology allows for a higher degree of dosimetry individualization than the MIRD methodology, which in some cases leads to important differences in dose values. Dosimetry of FCH-PET based on a single partial PET study seems viable due to the particular biokinetics of FCH, even though some correction factors may need to be applied to estimate mean skin/bone doses.